Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER TEENS
NCT04596631Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2020
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04596631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596631.